Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

Eric Simpson; Joseph Merola; Jonathan Silverberg; Rebecca Zachariae; Rebecca Olsen; Andreas Wollenberg

doi:10.25251/skin.5.supp.11

Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.11 ◽

2021 ◽

Vol 5 (1) ◽

pp. s11

Author(s):

Eric Simpson ◽

Joseph Merola ◽

Jonathan Silverberg ◽

Rebecca Zachariae ◽

Rebecca Olsen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pooled Analysis ◽

Adult Patients ◽

Severe Atopic Dermatitis ◽

Phase 2 ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

Abstract not available.

Download Full-text

Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.56 ◽

2021 ◽

Vol 5 (6) ◽

pp. s56

Author(s):

Thomas Bieber ◽

Lisa Beck ◽

Andrew Pink ◽

Hidehisa Saeki ◽

Lawrence Eichenfeld ◽

...

Keyword(s):

Atopic Dermatitis ◽

Microbial Diversity ◽

Controlled Trial ◽

Adult Patients ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

N/A

Download Full-text

26292 Rapid improvement in skin pain, and its impact on quality of life, in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.402 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB96

Author(s):

David Rosmarin ◽

Scott Fretzin ◽

Lindsay Strowd ◽

Marta Casillas ◽

Amy DeLozier ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Severe Atopic Dermatitis ◽

Rapid Improvement ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Skin Pain

Download Full-text

28170 Neutralizing interleukin-13 increases skin microbial diversity: Results from a phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.722 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB177

Author(s):

Thomas Bieber ◽

Lisa A. Beck ◽

Andrew Pink ◽

Hidehisa Saeki ◽

Lawrence Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Microbial Diversity ◽

Controlled Trial ◽

Adult Patients ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

Download Full-text

Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.9 ◽

2021 ◽

Vol 5 (1) ◽

pp. s9

Author(s):

Jonathan Silverberg ◽

Sebastien Barbarot ◽

Melinda Gooderham ◽

Jan Simon ◽

Eric Simpson ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

Abstract not available.

Download Full-text

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Download Full-text

Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.57 ◽

2021 ◽

Vol 5 (6) ◽

pp. s57

Author(s):

Andrew Blauvelt ◽

Anderas Wollenberg ◽

Andrew Pink ◽

Ketty Peris ◽

April Armstrong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo ◽

Term Maintenance

N/A

Download Full-text

Results from a randomized, double-blind, placebo-controlled, exploratory, multicenter study of GBR 830 in adult patients with moderate-to-severe atopic dermatitis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.976 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB245

Keyword(s):

Atopic Dermatitis ◽

Multicenter Study ◽

Adult Patients ◽

Severe Atopic Dermatitis ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(21)00589-4 ◽

2021 ◽

Cited By ~ 1

Author(s):

Kristian Reich ◽

Henrique D Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Download Full-text

28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.723 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB177

Author(s):

Andrew Blauvelt ◽

Andreas Wollenberg ◽

Andrew Pink ◽

Ketty Peris ◽

April Armstrong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo ◽

Term Maintenance

Download Full-text

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

JAAD International ◽

10.1016/j.jdin.2021.11.001 ◽

2022 ◽

Vol 6 ◽

pp. 27-36

Author(s):

Norito Katoh ◽

Yukihiro Ohya ◽

Hiroyuki Murota ◽

Masanori Ikeda ◽

Xiaofei Hu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Blind Study ◽

Severe Atopic Dermatitis ◽

Double Blind Study ◽

Phase 3 ◽

Double Blind ◽

Topical Corticosteroids

Download Full-text